Tiny Biotechs Dancing in the Bull Pen
Hemispherx is expecting an FDA decision Tuesday on the company's drug for chronic fatigue syndrome, Ampligen, based on a single study completed in 2004. The FDA refused to review the Ampligen application in 2007, but Hemispherx resubmitted the drug in 2008. The company has outstanding manufacturing problems related to Ampligen that have yet to be resolved, according to the company's SEC filings.
At various times over the years, Hemispherx has claimed Ampligen as a treatment for HIV, the ebola virus, avian flu, swine flu and smallpox.
Hemispherx sold stock to raise cash on May 11 and again on May 19, a strange move for a company confident about a positive decision on Ampligen next week.
OncoGenex shares took off May 14 after a research abstract for the firm's prostate cancer drug OGX-011 was released online in advance of the ASCO meeting. The interim data from a phase II study showed OGX-011 plus chemotherapy boosted survival over chemotherapy alone in patients with advanced prostate cancer.Rodman & Renshaw, an investment bank that caters to raising money for small-cap biotech companies, initiated coverage on OncoGenex with a buy rating, making the claim that OGX-011 could be a more effective prostate cancer drug than Dendreon's (DNDN) Provenge. OncoGenex finished the first quarter with $9.4 million in cash, which makes it highly likely that a follow-on financing deal will get done soon, perhaps before or right after the ASCO meeting, where additional OGX-011 data will be presented.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV